EMD-51721

Single-particle
3.4 Å
EMD-51721
3D View Gallery
Deposition: 03/10/2024
Map released: 12/03/2025
Last modified: 12/03/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-51721

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-9gz3 summary report (pdf.gz) Map-9gz3 FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

Beta-cardiac heavy meromyosin motor domain in the primed state

EMD-51721

Single-particle
3.4 Å
EMD-51721
3D View Gallery
Deposition: 03/10/2024
Map released: 12/03/2025
Last modified: 12/03/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: Beta-cardiac heavy meromyosin in the primed state
Fitted models: 9gz3

Deposition Authors: McMillan SN , Pitts JRT , Barua B, Winkelmann DA , Scarff CA
Mavacamten inhibits myosin activity by stabilising the myosin interacting-heads motif and stalling motor force generation.
McMillan SN , Pitts JRT , Barua B, Winkelmann DA , Scarff CA
(2025) bioRxiv
PUBMED: 39990378
DOI: doi:10.1101/2025.02.12.637875
ISSN: 2692-8205
Grant Support: